Novartis Investigative Site

Tacoma, Washington 98418

0 studies enrolling now · 38 studies all time

What they study most

Advancing Multiple Sclerosis, Alzheimers Disease, Atherosclerosis, Breast Cancer, Breast Neoplasms, COPD, Cancer, Carcinoma, Renal Cell, Cardiovascular Disease and Lipoprotein(a), Chronic Heart Failure (CHF), Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD)

Studies at this site

• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D — Completed
• Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer — Completed
• A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer — Completed
• Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction — Completed
• Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia — Completed
• Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies — Completed
• Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. — Completed
• Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients. — Completed
• Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes. — Completed
• A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod — Completed
• A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease — Stopped early
• Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer — Completed
• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. — Completed
• A Study of CLR325 in Chronic Stable Heart Failure Patients. — Completed
• A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure — Stopped early
• Study of Secukinumab With 2 mL Pre-filled Syringes — Completed
• Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone — Stopped early
• Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC — Completed
• A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors — Completed
• Study To Assess Long Term Safety Of Pazopanib — Completed
• GSK1120212 Rollover Study — Stopped early
• Efficacy and Safety Study of QVA149 in COPD Patients — Completed
• EXTEND (Eltrombopag Extended Dosing Study) — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
• EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer — APPROVED_FOR_MARKETING
• A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation. — Completed
• Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients — Completed
• Safety and Tolerability of BVS857 in Subjects With Insulin Resistance — Completed
• NVA237 BID Versus Placebo Twelve-week Efficacy Study — Completed
• Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis — Completed
• Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations — Completed
• Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease — Completed
• Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol — Completed